Drug prices in TV ads again? Sen­a­tors take an­oth­er swing with ex­pe­dit­ed bill

Last year
Pharma
Marketing

No­vo Nordisk ramps up le­gal case against com­pound­ing phar­ma­cies sell­ing 'mis­brand­ed' semaglu­tide

Last year
Pharma
Law

FDA ships Form 483 to gener­ic drug gi­ant Dr. Red­dy’s due to equip­ment is­sues, oth­er ob­ser­va­tions

Last year
Pharma
FDA+

GSK is win­ning 70% of the RSV mar­ket, while Pfiz­er's launch has left it ‘dis­ap­point­ed’ so far

Last year
Pharma

2024 VC fore­cast: Clin­i­cal-stage CD­MOs like­ly to have uptick in de­mand but spe­cial­iza­tion crit­i­cal

Last year
Manufacturing

Charles Riv­er works on rare dis­ease gene ther­a­py; Emer­gent gets $75M for an­thrax vac­cine; Eu­roAPI hires new COO 

Last year
Manufacturing

Flag­ship aims to raise $3B; Phe­nom­ic inks an­oth­er phar­ma deal; On­covi­ta gets €8M for can­cer vac­cine

Last year
News Briefing

Cy­bin gears up for reg­is­tra­tional tri­al of psilo­cy­bin ana­log in ma­jor de­pres­sion af­ter PhII suc­cess

Last year
R&D

Cell man­u­fac­tur­ing com­pa­ny rais­es $19M Se­ries A to in­crease ca­pac­i­ty, staff num­bers 

Last year
Financing
Manufacturing

Up­dat­ed: Ab­b­Vie to ac­quire Im­muno­Gen for $10B in ban­ner year for AD­Cs

Last year
Deals
Pharma

Ex­clu­sive: No­vo foun­da­tion's growth arm is mak­ing an in­vest­ment push in­to health­care, ex­pand­ing be­yond life sci­ences

Last year
Financing
Health Tech

CRO Fortrea 'dis­putes the ac­cu­ra­cy' of Ace­lyrin's claims about im­munol­o­gy drug tri­al con­duct

Last year
R&D
Outsourcing

Luke Miels sheds light on GSK in­ter­nal changes, ‘very busy’ BD scene

Last year
Pharma

Xenon of­fers $300M in shares af­ter tout­ing path ahead for MDD pro­gram de­spite PhII miss

Last year
Financing
R&D

Or­na Ther­a­peu­tics trims staff in ‘de­fen­sive re­duc­tion’ de­spite large fi­nanc­ing hauls

Last year
People
Startups

Clin­i­cians say ben­e­fits of CAR-T con­tin­ue to out­weigh risk of T-cell ma­lig­nan­cies

Last year
Pharma
Cell/Gene Tx

Health tech stands out as a top area for ear­ly-stage VC fund­ing in Q3

Last year
Financing
Health Tech

Sen­ate Fi­nance Com­mit­tee to re­view fed­er­al poli­cies on drug short­ages

Last year
FDA+
Law

Ab­b­Vie is gun­ning for ac­cel­er­at­ed ap­proval of an­ti­body-drug con­ju­gate af­ter pos­i­tive PhII da­ta

Last year
R&D
Pharma

Gilead­'s cell ther­a­py busi­ness Kite cuts 7% of work­force

Last year
People
Cell/Gene Tx

Boehringer In­gel­heim and IBM team up to make an­ti­bod­ies with gen­er­a­tive AI

Last year
Deals
AI

Health in­sur­ance gi­ants Cigna and Hu­mana re­port­ed­ly in talks to merge

Last year
Health Tech

In­tas Phar­ma­ceu­ti­cal­s' In­di­an fa­cil­i­ty hit with FDA warn­ing let­ter, placed on im­port alert

Last year
FDA+
Manufacturing

Gen­er­a­tion Bio to lay off 68 em­ploy­ees in a dif­fi­cult year for non-vi­ral gene ther­a­py biotechs

Last year
People
Cell/Gene Tx
First page Previous page 238239240241242243244 Next page Last page
A service from the Financial Times